Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab dose-ranging in acute gout flares
NCT00798369Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Primary completion
- Aug 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of canakinumab in gout, sponsored by Novartis. Started Nov 2008; status: completed.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT00798369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00798369.